Does dental and oral health influence the development and course of bisphosphonate-related osteonecrosis of the jaws (BRONJ)?
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The main causes for the occurrence of bisphosphonate-related osteonecrosis of the jaws (BRONJ) are the application of aminobisphosphonates and the extraction of teeth. However, the question which factors in dental and oral health are relevant has not been answered completely.
Materials and methods
In a retrospective study, 50 patients who were treated with BRONJ between 2000 and 2009 were analyzed. As underlying diseases, they suffered from breast cancer (n = 24), multiple myeloma (n = 16), prostate cancer (n = 5), osteoporosis (n = 4), and kidney cancer (n = 1). The data were collected from the patient charts of the treating dentists, oral and maxillofacial surgeons, general practitioners, and oncologists. The time of occurrence of BRONJ after treatment onset with bisphosphonates (BP) was examined with Kaplan–Meier estimator and logrank test (level of significance 0.05).
At the time of BP treatment, onset the decayed, missing, and filled teeth (DMFT) index was 20.5 ± 4.2. Patients with a DMFT value less than 20 showed a significantly longer BRONJ-free time interval after BP treatment onset with 39.7 ± 1.1 months compared to patients with a DMFT value higher than 20, in whom BRONJ appeared after 14.4 ± 2.8 months (p < 0.001). However, the DMFT value had no influence on the success rate of BRONJ treatment.
As a pre-existing oral disease, 60 % of the patients (n = 30) had marginal periodontitis; 38 % (n = 19), apical periodontitis; and 22 % (n = 11), a pressure lesion from their dentures.
In patients with marginal periodontitis, BRONJ occurred after 26.3 months (range 20.9–31.3) and in patients without marginal periodontitis, after 27.4 months (range 14.6–40.1) (p = 0.58). Only 20 % of the patients with marginal periodontitis received adequate treatment. Without parodontal treatment, BRONJ occurred 15 months earlier compared to patients with parodontal treatment (p = 0.12). The state of the periodontium did not influence the healing rate of BRONJ (p > 0.999).
The present study highlights the great benefit of good dental and oral health in the prevention of BRONJ; but it also shows that after the appearance of BRONJ, these factors do no longer seem to play a relevant role in the disease course.
- Marx, R (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61: pp. 1115-1117 CrossRef
- Allen, M, Burr, DB (2009) The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 67: pp. 61-70 CrossRef
- Ruggiero, S, Dodson, TB, Assael, LA, Landsberg, R, Marx, RE, Mehrota, B (2009) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws—2009 update. J Oral Maxillofac Surg 67: pp. 2-12 CrossRef
- Fehm, T, Beck, V, Banys, M, Lipp, HP, Hairass, M, Reinert, S, Solomayer, EF, Wallwiener, D, Krimmel, M (2009) Bisphosphonate-induced osteonecrosis of the jaw (ONJ): incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecol Oncol 112: pp. 605-609 CrossRef
- Jadu, F, Lee, L, Pharoah, M, Reece, D, Wang, L (2007) A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol 18: pp. 2015-2019 CrossRef
- Durie, B, Katz, M, Crowley, J (2005) Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353: pp. 99-102 CrossRef
- Badros, A, Weikel, D, Salama, A, Goloubeva, O, Schneider, A, Rapoport, A, Fenton, R, Gahres, N, Sausville, E, Ord, R, Meiller, T (2006) Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 24: pp. 945-952 CrossRef
- Hoff, A, Toth, BB, Altundag, K, Johnson, MM, Warneke, CL, Hu, M, Nooka, A, Sayegh, G, Guarneri, V, Desrouleaux, K, Cui, J, Adamus, A, Gagel, RF, Hortobagyi, GN (2008) Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23: pp. 826-836 CrossRef
- Melo, M, Obeid, G (2005) Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition. J Am Dent Assoc 136: pp. 1675-1681 CrossRef
- Micheelis, W, Hoffmann, T, John, M, Kerschbaum, T, Potthoff, P, Reich, E, Reis, U, Reiter, F, Schiffner, U, Schroeder, E (2005) Vierte Deutsche Mundgesundheitsstudie (DMS IV). Neue Ergebnisse zu oralen Erkrankungsprävalenzen, Risikogruppen und zum zahnärztlichen Versorgungsgrad in Deutschland. Deutscher Zahnärzteverlag DÄV 31: pp. 22-25
- Marx, R, Sawatari, Y, Fortin, M, Broumand, V (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63: pp. 1567-1575 CrossRef
- Hoff, A, Toth, BB, Altundag, K, Guarneri, V, Adamus, A, Nooka, AK, Sayegh, GG, Johnson, MM, Gagel, RF, Hortobagyi, GN (2006) Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. ASCO Annual Meeting Proceedings (post meeting edition). J Clin Oncol 24: pp. 8528
- Woo, S, Hellstein, JW, Kalmar, JR (2006) Systematic review: bisphosphonate and osteonecrosis of the jaws. Ann Intern Med 144: pp. 753-761 CrossRef
- Ripamonti, C, Maniezzo, M, Campa, T, Fagnoni, E, Brunelli, C, Saibene, G, Bareggi, C, Ascani, L, Cislaghi, E (2008) Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 20: pp. 137-145 CrossRef
- Kyrgidis, A, Vahtsevanos, K, Koloutsos, G, Andreadis, C, Boukovinas, I, Teleioudis, Z, Patrikidou, A, Triaridis, S (2008) Bisphosphonate-related osteonecrosis of the jaws: a case–control study of risk factors in breast cancer patients. J Clin Oncol 26: pp. 4634-4638 CrossRef
- Wyngaert, T, Huizing, MT, Vermorken, JB (2006) Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy?. Ann Oncol 17: pp. 1197-1204 CrossRef
- Abu-Id, A, Kreusch, G (2006) Bisphosphonatassoziierte Osteonekrose des Kiefers. Mund Kiefer Gesichts Chir 10: pp. 73-81 CrossRef
- Carlson, E, Basile, JD (2009) The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 67: pp. 85-95 CrossRef
- AAOMS, 2007, American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 369–376
- Corso, A, Varettoni, M, Zappasodi, P, Klersy, C, Mangiacavalli, S, Pica, G, Lazzarino, M (2007) A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 21: pp. 1545-1548 CrossRef
- Does dental and oral health influence the development and course of bisphosphonate-related osteonecrosis of the jaws (BRONJ)?
Oral and Maxillofacial Surgery
Volume 18, Issue 2 , pp 213-218
- Cover Date
- Print ISSN
- Online ISSN
- Springer Berlin Heidelberg
- Additional Links
- Bisphosphonate-related osteonecrosis of the jaws
- Oral health
- Dental health
- Marginal periodontitis
- Industry Sectors